Avelas Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Avelas Biosciences, Inc. - overview
Location
-, CA-California, US
Primary Industry
Biotechnology
About
Avelas Biosciences, Inc. develops innovative diagnostic solutions aimed at improving cancer treatment outcomes through advanced technologies, enhancing patient care and precision medicine. Avelas Biosciences specializes in the development of diagnostics for cancer treatment. The company raised USD 20.
000 mn in Series C financing in August 2016, led by Pharmstandard International and supported by investors like Ervington Investments Limited and Alexandria Venture Investments. Avelas is headquartered in the US. The founder, whose previous ventures are not documented, has a background in the biotech sector. Avelas Biosciences offers diagnostic solutions designed to enhance cancer treatment decision-making.
Their product suite includes advanced imaging technologies and molecular diagnostics aimed at improving the precision of cancer therapies. These solutions target healthcare providers and oncologists, facilitating better patient outcomes through personalized treatment approaches. Avelas serves clients primarily in North America, with a focus on innovative solutions that address the complexities of cancer care. Avelas Biosciences generates revenue through a combination of product sales and partnerships with healthcare institutions.
Their financial model is built on transactional sales of diagnostic products, in addition to collaborative agreements with medical facilities that enhance service offerings. This diversified approach aims to strengthen their revenue base while fostering long-term relationships with healthcare providers. Avelas Biosciences is focused on expanding its portfolio with new diagnostic products aimed at enhancing cancer treatment effectiveness. The company plans to introduce additional technologies by 2025, targeting new markets in Europe and Asia to broaden its global reach.
The recent funding of USD 20. 000 mn will support these initiatives, particularly in product development and market expansion efforts, enhancing their capacity to deliver innovative solutions in oncology.
Current Investors
Avalon Ventures, Alexandria Venture Investments, 6 Dimensions Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.avelasbio.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Avelas Biosciences, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C | Completed | Avelas Biosciences, Inc. | - | ||||||||
| Series B | Completed | Avelas Biosciences, Inc. | - | ||||||||
| Series B | Completed | Avelas Biosciences, Inc. | - | ||||||||
| Series A | Completed | Avelas Biosciences, Inc. | - |
Displaying 1 - 4 of 4
Avelas Biosciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.